Horizon Pharma (HZNP) Tops Q4 EPS by 13c, Offers FY Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. CRWD
2. AAPL
3. PLTR
4. LITE
5. REGN
6. ABBV
7. MRVL
8. CL
9. CHKP
10. MAR

Go back to Horizon Pharma (HZNP) Tops Q4 EPS by 13c, Offers FY Guidance

Horizon Pharma plc (HZNP) Reports Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for Treatment of Active Thyroid Eye Disease (TED) Met Primary & All Secondary Endpoints

February 28, 2019 7:22 AM EST

Horizon Pharma plc (NASDAQ: HZNP) today announced topline results from its Phase 3 confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease (TED). The study met its primary endpoint, showing more patients treated with teprotumumab compared with placebo had a meaningful... More

Horizon Pharma (HZNP) PT Raised to $26 at Cantor Fitzgerald

February 27, 2019 11:41 AM EST

Cantor Fitzgerald analyst Louise Chen raised the price target on Horizon Pharma (NASDAQ: HZNP) to $26.00 (from $23.00) while maintaining a Overweight rating.

Chen commented, "The increase in our PT is driven by upwards earnings revisions. We use a blend of DCF... More